Literature DB >> 15963324

Agents for the Treatment of Multidrug-resistant Gram-positive Endocarditis.

Jennifer K Long1.   

Abstract

Several newer agents with activity against multidrug- resistant gram-positive pathogens are available. These agents have in vitro and clinical data supporting their utility in the treatment of infections caused by pathogens such as methicillin-resistant staphylococci and vancomycin-resistant enterococci. Daptomycin appears to be rapidly bactericidal, and linezolid and quinupristin/dalfopristin also are cidal against staphylococci. Although the agents have several properties that are attractive for use in endocarditis, clinical data are limited. Further investigation with each agent and combination therapy are warranted before definitive recommendations can be made.

Entities:  

Year:  2005        PMID： 15963324     DOI： 10.1007/s11908-005-0055-4

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.725


  39 in total

1.  Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium.

Authors:  Inmaculada A Herrero; Nicolas C Issa; Robin Patel
Journal:  N Engl J Med       Date:  2002-03-14       Impact factor: 91.245

2.  Occurrence of MRSA endocarditis during linezolid treatment.

Authors:  E H Ben Mansour; E Jacob; M Monchi; D Ledoux; J-L Canivet; P De Mol; P Damas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-05-27       Impact factor: 3.267

3.  Time-dependent antibacterial effects of linezolid in experimental rabbit endocarditis.

Authors:  Lewis V Buchanan; Charlene F Dailey; Richelle J LeMay; Raymond J Zielinski; Ming-Shang T Kuo; John K Gibson
Journal:  J Antimicrob Chemother       Date:  2002-09       Impact factor: 5.790

4.  Nosocomial superinfections due to linezolid-resistant Enterococcus faecalis: evidence for a gene dosage effect on linezolid MICs.

Authors:  Kathleen A Ruggero; Laura K Schroeder; Paul C Schreckenberger; Alexander S Mankin; John P Quinn
Journal:  Diagn Microbiol Infect Dis       Date:  2003-11       Impact factor: 2.803

5.  Successful treatment of vancomycin-resistant Enterococcus faecium endocarditis with linezolid in a renal transplant recipient with human immunodeficiency virus infection.

Authors:  S Archuleta; B Murphy; M J Keller
Journal:  Transpl Infect Dis       Date:  2004-09       Impact factor: 2.228

6.  Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid.

Authors:  H M Babcock; D J Ritchie; E Christiansen; R Starlin; R Little; S Stanley
Journal:  Clin Infect Dis       Date:  2001-04-09       Impact factor: 9.079

7.  The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group.

Authors:  R C Moellering; P K Linden; J Reinhardt; E A Blumberg; F Bompart; G H Talbot
Journal:  J Antimicrob Chemother       Date:  1999-08       Impact factor: 5.790

8.  Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.

Authors:  Kerry L LaPlante; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

9.  Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Authors:  Fu-Yu Chiang; Michael Climo
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

10.  Failure of linezolid treatment for enterococcal endocarditis.

Authors:  S M Zimmer; A M Caliendo; M C Thigpen; J Somani
Journal:  Clin Infect Dis       Date:  2003-07-16       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.